Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy

Journal of Clinical Investigation

Volumn 127, Issue 2, 2017, Pages 720-734

  Alcacer, Cristina ^a   Andreoli, Laura ^a   Sebastianutto, Irene ^a   Jakobsson, Johan ^b   Fieblinger, Tim ^a   Cenci, Maria Angela ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE N OXIDE; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUSCARINIC M3 RECEPTOR; PHOSPHOPROTEIN; QUINPIROLE; VIRUS VECTOR; DOPAMINE 2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MOVEMENT; CELL ACTIVATION; CHEMOGENETIC STIMULATION; CONTROLLED STUDY; DISEASE SEVERITY; DORSOLATERAL STRIATUM; DYSKINESIA; FORELIMB; GENOTYPE; IMMUNOREACTIVITY; LEVODOPA-INDUCED DYSKINESIA; MOTOR ACTIVITY; MOUSE; NERVE CELL; NERVE CELL STIMULATION; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROMODULATION; NONHUMAN; OPEN FIELD TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRIATAL PROJECTION NEURON; AGONISTS; ANIMAL; CHEMICALLY INDUCED; GENETICS; HUMAN; METABOLISM; NERVE TRACT; PARKINSON DISEASE, SECONDARY; PATHOLOGY; RAT; TRANSGENIC MOUSE; VISUAL CORTEX;

ANIMALS; HUMANS; LEVODOPA; MICE; MICE, TRANSGENIC; NEURAL PATHWAYS; NEURONS; PARKINSON DISEASE, SECONDARY; RATS; RECEPTOR, MUSCARINIC M3; RECEPTORS, DOPAMINE D2; VISUAL CORTEX;

EID: 85014068728     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI90132     Document Type: Article

References (68)

1. Gerfen CR, Surmeier DJ. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci. 2011;34:441-466.
2. Cui G, et al. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature. 2013;494(7436):238-242.
3. Jin X, Tecuapetla F, Costa RM. Basal ganglia subcircuits distinctively encode the parsing and concatenation of action sequences. Nat Neurosci. 2014;17(3):423-430.
4. Surmeier DJ, Graves SM, Shen W. Dopaminergic modulation of striatal networks in health and Parkinson's disease. Curr Opin Neurobiol. 2014;29:109-117.
5. Wiecki TV, Frank MJ. Neurocomputational models of motor and cognitive deficits in Parkinson's disease. Prog Brain Res. 2010;183:275-297.
6. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366-375.
7. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13(7):281-285.
8. Kravitz AV, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010;466(7306):622-626.
9. Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: A critical reappraisal. Nat Neurosci. 2014;17(8):1022-1030.
10. Cazorla M, Kang UJ, Kellendonk C. Balancing the basal ganglia circuitry: A possible new role for dopamine D2 receptors in health and disease. Mov Disord. 2015;30(7):895-903.
11. Tecuapetla F, Jin X, Lima SQ, Costa RM. Complementary Contributions of Striatal Projection Pathways to Action Initiation and Execution. Cell. 2016;166(3):703-715.
12. Schneider SA, Obeso JA. Clinical and pathological features of Parkinson's disease. Curr Top Behav Neurosci. 2015;22:205-220.
13. Lou JS, Kearns G, Benice T, Oken B, Sexton G, Nutt J. Levodopa improves physical fatigue in Parkinson's disease: A double-blind, placebocontrolled, crossover study. Mov Disord. 2003;18(10):1108-1114.
14. Suppa A, et al. The effect of L-dopa in Parkinson's disease as revealed by neurophysiological studies of motor sensory functions. Expert Rev Neurother. 2017;17(2):181-192.
15. Manson A, Stirpe P, Schrag A. Levodopainduced-dyskinesias clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis. 2012;2(3):189-198.
16. Bastide MF, et al. Pathophysiology of L-DOPAinduced motor and non-motor complications in Parkinson's disease. Prog Neurobiol. 2015;132:96-168.
17. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9(11):1106-1117.
18. Gong S, et al. Targeting Cre recombinase to specific neuron populations with bacterial artificial chromosome constructs. J Neurosci. 2007;27(37):9817-9823.
19. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. Proc Natl Acad Sci U S A. 2007;104(12):5163-5168.
20. Jain S, Ruiz de Azua I, Lu H, White MF, Guettier JM, Wess J. Chronic activation of a designer G(q)-coupled receptor improves β cell function. J Clin Invest. 2013;123(4):1750-1762.
21. Roth BL. DREADDs for Neuroscientists. Neuron. 2016;89(4):683-694.
22. Alcacer C, Santini E, Valjent E, Gaven F, Girault JA, Hervé D. Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci. 2012;32(17):5900-5910.
23. Bateup HS, et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A. 2010;107(33):14845-14850.
24. Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPAinduced dyskinesia and histone activation. Biol Psychiatry. 2009;66(6):603-613.
25. Francardo V, Recchia A, Popovic N, Andersson D, Nissbrandt H, Cenci MA. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol Dis. 2011;42(3):327-340.
26. Heiman M, et al. Molecular adaptations of striatal spiny projection neurons during levodopainduced dyskinesia. Proc Natl Acad Sci U S A. 2014;111(12):4578-4583.
27. Santini E, et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem. 2009;108(3):621-633.
28. Santini E, et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci. 2007;27(26):6995-7005.
29. Shen W, et al. M4 muscarinic receptor signaling ameliorates striatal plasticity deficits in models of L-DOPA-induced dyskinesia. Neuron. 2016;90(5):1139.
30. Mallet N, Ballion B, Le Moine C, Gonon F. Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. J Neurosci. 2006;26(14):3875-3884.
31. Cenci MA, Whishaw IQ, Schallert T. Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci. 2002;3(7):574-579.
32. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology. 2000;39(5):777-787.
33. Cenci MA. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci. 2007;30(5):236-243.
34. Feyder M, Bonito-Oliva A, Fisone G. L-DOPAinduced dyskinesia and abnormal signaling in striatal medium spiny neurons: focus on dopamine d1 receptor-mediated transmission. Front Behav Neurosci. 2011;5:71.
35. Murer MG, Moratalla R. Striatal signaling in L-DOPA-induced dyskinesia: common mechanisms with drug abuse and long term memory involving d1 dopamine receptor stimulation. Front Neuroanat. 2011;5:51.
36. Farrell MS, et al. A Gαs DREADD mouse for selective modulation of cAMP production in striatopallidal neurons. Neuropsychopharmacology. 2013;38(5):854-862.
37. Sindreu CB, Scheiner ZS, Storm DR. Ca2+-stimulated adenylyl cyclases regulate ERK-dependent activation of MSK1 during fear conditioning. Neuron. 2007;53(1):79-89.
38. Fieblinger T, et al. Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia. Nat Commun. 2014;5:5316.
39. Planert H, Berger TK, Silberberg G. Membrane properties of striatal direct and indirect pathway neurons in mouse and rat slices and their modulation by dopamine. PLoS ONE. 2013;8(3):e57054.
40. Cenci MA. Presynaptic mechanisms of L-DOPAinduced dyskinesia: The findings, the debate, and the therapeutic implications. Front Neurol. 2014;5:242.
41. Nutt JG, Holford NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol. 1996;39(5):561-573.
42. Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord. 2000;15(1):3-8.
43. Aubert I, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol. 2005;57(1):17-26.
44. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry. 2007;62(7):800-810.
45. Suárez LM, et al. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry. 2014;75(9):711-722.
46. Bagetta V, et al. Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. J Neurosci. 2012;32(49):17921-17931.
47. Bhide N, Lindenbach D, Barnum CJ, George JA, Surrena MA, Bishop C. Effects of the betaadrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat. J Neurochem. 2015;134(2):222-232.
48. Gomez-Mancilla B, Bédard PJ. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Exp Neurol. 1992;117(2):185-188.
49. Dobbs LK, Kaplan AR, Lemos JC, Matsui A, Rubinstein M, Alvarez VA. Dopamine Regulation of Lateral Inhibition between Striatal Neurons Gates the Stimulant Actions of Cocaine. Neuron. 2016;90(5):1100-1113.
50. Taverna S, Ilijic E, Surmeier DJ. Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J Neurosci. 2008;28(21):5504-5512.
51. Bez F, Francardo V, Cenci MA. Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion. Neurobiol Dis. 2016;94:213-225.
52. Creese I, Iversen SD. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res. 1973;55(2):369-382.
53. Nakajima K, et al. Gs-coupled GPCR signalling in AgRP neurons triggers sustained increase in food intake. Nat Commun. 2016;7:10268.
54. Gerfen CR, Miyachi S, Paletzki R, Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci. 2002;22(12):5042-5054.
55. Fieblinger T, et al. Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. J Neurosci. 2014;34(13):4728-4740.
56. Cerovic M, et al. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia. Biol Psychiatry. 2015;77(2):106-115.
57. Picconi B, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 2003;6(5):501-506.
58. Corvol JC, et al. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J Neurosci. 2004;24(31):7007-7014.
59. Marcotte ER, Sullivan RM, Mishra RK. Striatal G-proteins: effects of unilateral 6-hydroxydopamine lesions. Neurosci Lett. 1994;169(1-2):195-198.
60. Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res. 2010;183:183-208.
61. Cenci MA, Ohlin KE, Odin P. Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol Disord Drug Targets. 2011;10(6):670-684.
62. Marino MJ, et al. Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A. 2003;100(23):13668-13673.
63. Atasoy D, Aponte Y, Su HH, Sternson SM. A FLEX switch targets Channelrhodopsin-2 to multiple cell types for imaging and long-range circuit mapping. J Neurosci. 2008;28(28):7025-7030.
64. Charbonnier-Beaupel F, et al. Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinesia. J Neurosci. 2015;35(1):96-111.
65. Frau R, Pillolla G, Bini V, Tambaro S, Devoto P, Bortolato M. Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice. Psychoneuroendocrinology. 2013;38(4):542-551.
66. Paul ML, Graybiel AM, David JC, Robertson HA. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J Neurosci. 1992;12(10):3729-3742.
67. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci. 2002;15(1):120-132.
68. Lundblad M, Picconi B, Lindgren H, Cenci MA. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis. 2004;16(1):110-123.